IMB Dx, Inc. (KOSDAQ:461030)

South Korea flag South Korea · Delayed Price · Currency is KRW
9,550.00
+20.00 (0.21%)
Jan 29, 2026, 3:30 PM KST
-7.10%
Market Cap133.87B
Revenue (ttm)4.26B +10.0%
Net Income-7.99B
EPS-569.75
Shares Out14.02M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume138,959
Average Volume144,912
Open9,490.00
Previous Close9,530.00
Day's Range9,210.00 - 9,690.00
52-Week Range7,180.00 - 14,430.00
Betan/a
RSI45.84
Earnings Daten/a

About IMB Dx

IMB Dx, Inc. provides liquid biopsy platform in South Korea. It offers AlphaLiquid Platform that provides circulation-tumor DNA-based precision diagnostics solutions across various stages of cancer for patients, survivors, and individuals; and AlphaLiquid 100 test, a tool that enables the detection of biomarkers across 118 cancer-related genes through one blood test. The company also provides CancerDetect, a liquid biopsy platform for the early detection of cancer recurrence post-surgery; and CancerFind, a blood-based test for various cancer ea... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2018
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 461030
Full Company Profile

Financial Performance

In 2024, IMB Dx's revenue was 3.41 billion, a decrease of -15.40% compared to the previous year's 4.03 billion. Losses were -9.58 billion, -8.06% less than in 2023.

Financial Statements